Agenus (AGEN) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Agenus (AGEN) has outperformed Upstream Bio (UPB) over the past year, gaining 80.8% versus a loss of 76.0%. Agenus is the larger company by market cap ($346.8 million vs $251.9 million), about 1.4 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | UPB |
|---|---|---|
| Share price | $7.68 | $4.60 |
| Market cap | $346.84M | $251.95M |
| 1-day change | +1.86% | +1.10% |
| YTD return | +140.13% | -83.24% |
| 1-year return | +80.82% | -75.95% |
| 5-year return | -92.77% | — |
| P/E ratio (TTM) | 3.04 | — |
| EPS (TTM) | $2.53 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $33.68 |
| 52-week low | $2.71 | $4.37 |
| Distance from 52-week high | -25.51% | -86.34% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +242.84% | +576.96% |
| Average volume | 4.26M | 647.42K |
| Shares outstanding | 45.16M | 54.77M |
| Employees | 81 | 75 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed UPB by 156.8 percentage points over the past year.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 81 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees
AGEN vs UPB FAQ
Which is bigger, Agenus or Upstream Bio?
Agenus (AGEN) is larger, with a market capitalization of $346.84M compared with $251.95M for Upstream Bio (UPB).
Which stock has performed better over the past year, AGEN or UPB?
AGEN returned +80.82% over the past 12 months, compared with -75.95% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and Upstream Bio in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Agenus and Biotechnology: Pharmaceutical Preparations for Upstream Bio.